Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

8.005 +0.535 (+7.16%)
Streaming Delayed Price Updated: 3:08 PM EDT, May 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
Via Investor Brand Network
Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
Via Investor Brand Network
Exposures Product Safety
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
From Cybin Inc.
Via Business Wire
InvestorkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
Via Investor Brand Network
Exposures Product Safety
Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Alliance Global Partners Healthcare Showcase on May 21
Via Investor Brand Network
Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB003 Depression Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at Milken Global Conference on Medical Breakthroughs
Via Investor Brand Network
Cybin to Participate at the 28th Annual Milken Institute Global Conference
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Expands Phase 3 Trial Network to 18 Sites for CYB003 in Depression
Via Investor Brand Network
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Forms Strategic Partnership With Osmind to Prepare for Mental Health Drug Commercialization
Via Investor Brand Network
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Q3 Financials, Advances Clinical Programs
Via Investor Brand Network
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program with Segal Trials for Phase 3 MDD Study
Via Investor Brand Network
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights 2024 Achievements and Outlines Key 2025 Milestones
Via Investor Brand Network
Exposures Product Safety
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Lytham Partners Healthcare Summit
Via Investor Brand Network
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Promising Advances in Depression and Anxiety Treatment at ACNP Annual Meeting
Via Investor Brand Network
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Announces Participation in Water Tower Research Fireside Chat
Via Investor Brand Network
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
From Cybin Inc.
Via Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Reports Sustained 12-Month Efficacy for CYB003 in Treating Major Depressive Disorder
Via Investor Brand Network
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
From Cybin Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.